Scholar Rock earnings beat by $0.03, revenue fell short of estimates
Scholar Rock (SRRK) reported Q3 EPS of -$0.81, beating estimates by $0.03, but revenue of $570K missed expectations of $1.43M. The stock is down 1.85% over 3 months but up 67.42% year-over-year. InvestingPro rates its financial health as 'fair performance'.
How this was made
The 30-second read
Why it matters
The earnings release provides the first public data on Q3 performance, offering traders fresh information on the company's financial health.
Market read
The report is a primary disclosure for a small-cap biotech, offering limited but actionable insight for niche investors.
What to watch
Cash runway and upcoming clinical trial milestones are not discussed but could drive future valuation.
Background
Scholar Rock is a micro-cap biotech firm listed on NASDAQ, known for its focus on research tools for the life sciences.
Ticker impact
Scholar Rock reported Q3 EPS of -0.81, beating estimates by $0.03, and revenue of $570K versus $1.43M consensus.
potential modest downside as revenue miss outweighs EPS beat
Small-cap earnings with modest beat on loss per share and a large revenue shortfall typically lead to limited price movement.
Market effects
Limited impact on biotech/clinical trial sector; earnings highlight revenue volatility for early-stage companies.
Primarily affects US micro-cap investors; no broader regional effect.
Minimal global relevance due to company size and niche focus.
Counterpoint
Despite revenue miss, the EPS beat could signal improving cost structure; potential upside if guidance improves.
Key entities
- CompanyScholar Rock
NASDAQ-listed biotech firm (SRRK).

